Shionogi targets JPY550B revenue through QOL focus and global expansion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 31 2025
0mins
Source: SeekingAlpha
Financial Performance: Shionogi & Co. reported Q3 FY2024 revenue of JPY333.6 billion, a slight year-over-year decrease, but an increase when excluding a one-time payment from the previous year. The HIV business showed strong growth, particularly in long-acting formulations, while domestic infectious disease treatments stabilized.
Strategic Outlook: The company plans to focus on expanding its quality of life (QOL) disease portfolio and has dissolved its joint venture with Ping An Insurance to accelerate drug launches in China. Management remains confident in achieving a revenue target of JPY550 billion for FY2025, despite concerns over market volatility and regulatory challenges.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
